Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Incubation period, clinical and lung CT features for early prediction of COVID-19 deterioration: development and internal verification of a risk model

Fig. 4

a The calibration curve showed high coherence between the predicted and actual probability of deterioration. b Decision curve of DRM-COVID-19; blue line: risk value. Light line: assume all patients are getting deterioration. Horizontal thin line: assumed no patient is getting deterioration. The chart shows the expected net benefit of each patient relative to the stability of any patient. The farther away the curve is from the horizontal thin line, the greater the clinical benefit. c Clinical impact curve of DRM-COVID-19 Of 1000 patients, the solid red line represents the total number of deterioration considered high-risk at each risk threshold. The blue dotted line shows how many people actually need to have deteriorated. d The scatter chart shows the predicted value distribution and median value of different severity cases. Meanwhile, the Kruskal–Wallis test showed a statistical difference between the stable and the other groups. DRM-COVID-19 deterioration risk model of COVID-19

Back to article page